Clinical Trial Update: Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of a synthetic vaccine in patients with chronic myeloid leukemia and minimal residual disease has completed and results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Synthetic vaccine (synthetic vaccine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myeloid Leukemia, Minimal Residual Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-02-25